Bridging the Gap: Bioptimus CEO Jean-Philippe Vert on Building the Foundational AI for Biology
In this deep-dive episode of the Empowered Paient Podcast, Jean-Philippe explains why understanding biology across all scales—from molecules to organs—is the key to unlocking the next generation of precision medicine.
Bioptimus featured on the Empowered Patient Podcast
Our Co-Founder and CEO, Jean-Philippe Vert, sat down with Karen Jagoda to discuss how Bioptimus is moving beyond the "siloed" nature of traditional biomedical research. In this deep-dive episode, Jean-Philippe explains why understanding biology across all scales—from molecules to organs—is the key to unlocking the next generation of precision medicine.
A few highlights from the conversation:
- The Problem of Silos: Historically, research has focused on specific layers, like genomics or cellular biology. Jean-Philippe discusses how Bioptimus is building an AI infrastructure that connects these dots to create a truly holistic view of human biology.
- H-Optimus in Action: A look at our foundation model for histopathology, which helps pathologists analyze biopsies with unprecedented detail by learning from billions of images.
- The Future of Clinical Trials: How "digital twins" and synthetic control arms can simulate treatment outcomes, lowering the cost of drug development and accelerating breakthroughs for rare diseases.
- Closing the Translational Gap: Why a unified AI model is the essential tool for moving discoveries from the lab to the patient more efficiently.
"What we are building at Bioptimus is an AI-intelligent system that can see across all these layers to get a holistic picture of biology. It’s not only a scientific endeavor; it’s about solving why so many diseases remain untreated today." — Jean-Philippe Vert
More videos like this:
Rewriting Rare Disease R&D with Foundation Models
Join our CEO Jean-Philippe Vert on the RARECast podcast to discover how we are using foundation models to rewrite rare disease R&D and repurpose existing drugs .
Mathilda Strom, Founding COO @Bioptimus | Slush 2024
At Slush 2024, our Founding COO Mathilda Strom took the stage to unveil how we at Bioptimus are building the world's first multiscale, multimodal foundation model for biology.
AI in Healthcare: Scaling Drug Discovery & Clinical Trials
Join our Founding COO Mathilda Strom on the Startup Scaleup People podcast to explore how we are using AI to fix the 90% clinical trial failure rate. In this episode, Mathilda shares insights from her 20-year career in scaling high-impact ventures and explains why Bioptimus is a different kind of deep-tech challenge.
Inside Bioptimus: Training (and Tracking) Foundation Models for Biology
Discover how we at Bioptimus track and refine our foundation models for biology, to make them learn the language of life so they can help you accelerate drug discovery and compress development timelines.
Bioptimus COO Mathilda Strom on AI, Compute, and the Future of Biological Foundation Models
Mathilda Strom, the Founding COO at Bioptimus, shares her journey from building startups across Africa, Asia, and Latin America to helping shape one of the most ambitious AI and biology projects on the planet.
Foundation Models for Biology, Across Scales
Discover how AI foundation models are revolutionising biology and drug discovery. Jean-Philippe Vert explores the future of multiscale virtual cells.
Mathilda Strom, Founding COO @Bioptimus | Slush 2024
Slush is a founder-focused annual event delivering actionable company-building advice while bringing together the who’s who in startups and tech.
Building an AI model for Biology
Could AI unlock the secrets of biology? In this WIRED Health 2025 Startup Pitch, Zelda Mariet, Principal Research Scientist and Co-Founder of Bioptimus, introduces their groundbreaking universal AI foundation model that connects biology at every scale - from molecules to cells, tissues, and organisms.
AI Is About to Simulate Human Biology
Can AI become a universal simulator of biology, helping predict disease, improve drug success rates, and reshape how medicine is developed? A thoughtful conversation on AI, biology, and the future of medicine. From lessons learned in big tech to what it takes to build enduring platforms in TechBio, this is a considered discussion for anyone interested in where scientific discovery is heading.